The EHMT1 Knockout HEK293T Polyclonal Cells provide a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population for the targeted disruption of the EHMT1 gene. This loss-of-function model is generated in the widely utilized HEK293T host cell line and enables systematic interrogation of EHMT1-dependent epigenetic regulation. The polyclonal format captures the full spectrum of editing events across the population, avoiding clonal bias while maintaining robust target-gene ablation. As a heterogeneous knockout pool, it is ideal for bulk functional assays where population-level effects reflect average gene disruption outcomes.
HEK293T cells are a derivative of the human embryonic kidney HEK293 line, stably expressing the SV40 large T antigen. This modification permits high-copy episomal replication of plasmids containing the SV40 origin, driving transient and stable overexpression of transgenes. The epithelial-like morphology and ease of transfection have made HEK293T a workhorse in molecular and cellular biology, commonly employed for recombinant protein production, viral packaging, and promoter activity studies. Their human origin and relatively normal karyotype render them suitable for mechanistic analyses of human gene function, particularly in the context of chromatin biology and transcriptional control.
EHMT1 encodes a histone lysine methyltransferase that specifically catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2). It functions predominantly within a stable heteromeric complex with the related methyltransferase EHMT2 (G9a), and this interaction is mediated by the adaptor protein WIZ. The complex recruits HP1 proteins and MPP8, promoting chromatin compaction and long-range transcriptional silencing. EHMT1 activity is regulated by several upstream factors: MDM2 influences its stability, while Aurora kinase B phosphorylates EHMT1 to modulate its chromatin association. Downstream targets of EHMT1-mediated H3K9 methylation include CDKN1A and BAX, linking epigenetic control to cell cycle and apoptosis, as well as a broad set of developmental regulator genes. Thus, EHMT1 serves as a central node connecting signaling inputs to chromatin structure and gene expression programs.
In the HEK293T background, disruption of EHMT1 removes a key eraser of euchromatic histone marks, leading to measurable alterations in H3K9 methylation patterns. This model allows dissection of EHMT1-specific functions decoupled from EHMT2 redundancy, a challenge in systems where both enzymes are expressed. The cells are particularly valuable for probing the direct transcriptional consequences of EHMT1 loss, as HEK293T cells support robust transient transfection of reporter constructs alongside CRISPR-mediated genome editing. Moreover, because HEK293T cells lack the developmental context of primary neurons, they offer a reductionist system to isolate core epigenetic mechanisms relevant to Kleefstra syndrome and other EHMT1-linked neurodevelopmental disorders.
Research applications for this knockout pool are extensive. Investigators can perform ChIP-qPCR to quantify genome-wide or locus-specific changes in H3K9me1/me2, Western blotting to confirm EHMT1 protein depletion and track downstream effectors, and RT-qPCR to measure de-repression of target genes such as CDKN1A. Immunofluorescence and co-immunoprecipitation assays enable visualization of altered chromatin architecture and disrupted complex formation with EHMT2 and WIZ. The cells also serve as a platform for evaluating small-molecule inhibitors of EHMT1 as potential therapeutics. Functional complementation by re-introducing wild-type or mutant EHMT1 can validate structure-function relationships. For further information on this product??s performance and recommended assay conditions, please contact Ascent Research.
